

Table S1. Study design for DILI prediction in multicenter retrospective dataset

		Cohort definitions	
Outcome	Drug		Criteria
Acute kidney injury	Losartan, candesartan, telmisartan, olmesartan, irbesartan, valsartan	Cohort entry events	-
		Inclusion criteria	Previous liver function test measures
			Without abnormal measures
			<p>Drug exposure (6 drugs) with inclusion criteria:</p> <ul style="list-style-type: none"> - observation period ≥ 60 days prior to prescription day <p>Entry events with at least 2 of the following criteria:</p> <ul style="list-style-type: none"> - having at least 1 measurement of AST, starting between 60 days before and 0 day after cohort entry start date. - having at least 1 measurement of ALT, starting between 60 days before and 0 day after cohort entry start date. - having at least 1 measurement of total bilirubin, starting between 60 days before and 0 day after cohort entry start date. - having at least 1 measurement of ALP, starting between 60 days before and 0 day after cohort entry start date. <p>Entry events with all of the following criteria:</p> <ul style="list-style-type: none"> - having at most 0 measurements of AST, starting between 60 days before and 0 day after cohort entry start date; high range-to-value ratio >1. - having at most 0 measurements of ALT, starting between 60 days before and 0 day after cohort entry start date; high range-to-value ratio >1. - having at most 0 measurements of ALP, starting between 60 days before and 0 day after cohort entry start date; high range-to-value ratio >1. - having at most 0 measurements of total bilirubin, starting between 60 days before and 0 day after cohort entry start date; high range-to-value ratio >1.
		Abnormal measures	<p>People enter the cohort when observing any of the following:</p> <ul style="list-style-type: none"> - measurements of ALT, high range-to-value ratio > 5. - measurements of ALP, high range-to-value ratio > 2. - measurements of total bilirubin, high range-to-value ratio >2; having at least 1 measurement of ALT, starting between 7 days before and 7 days after total bilirubin start date; high range-to-value ratio >3.

DILI: drug-induced liver injury, AST: alkaline phosphatase, ALT: alanine aminotransferase.